

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

SENTICOL III: a validation study


Amélie ANOTA, statistician, DRCI Besançon, France.
<u>Fabrice LECURU</u>, surgeon, GINECO, France.
Mario LEITAO, surgeon, MSKCC, USA.
Patrice MATHEVET, surgeon, CHUV, Switzerland.
Marie PLANTE, surgeon, CHU Quebec, Canada.

GYNECOLOGIC CANCER INTERGROUP

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

Cervical cancer: good candidate


- Low tumor load
 - ≤20% N+
 - 1 node in 50%
 - Small size
- Toxicity
 - Intraoperative complications
 - Lymphoceles 30%
 - Lymphedema 15%
- Failure
 - Nodal recurrence in N0 patients



Reiffenstuhl G & al

GYNECOLOGIC CANCER INTERGROUP

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers



GYNECOLOGIC CANCER INTERGROUP

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

≈150 valuable papers

Review and metaanalyses

Prospective trials Altgassen C & al 2008 (AGO) Darlin L & al 2010 Lécuru F & al 2011 Cormier B & al 2011 Mathevet P & al 2015 van de Lande J & al 2007 Selman T & al 2008 Eiriksson L & al 2010 Palla V & al 2014 Wang X & al 2015 Tax C & al 2016 Diab Y 2017

GYNECOLOGIC CANCER INTERGROUP

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

False negative risk

trained surgeon & team no nodal involvement (MRI, intraop exploration) combined technique tumor diameter ≤2cm (*) BILATERAL DETECTION ultrastaging

FN rate: 1/1257 (0.08%)

P Mathevet: Ultrastaging of NSLN SENTICOL I: 1 ITC

SENTICOL II: no FN

GYNECOLOGIC CANCER INTERGROUP

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

Enhanced pathological information serial sectioning and IHC PCR ITC <0.2mm, micromets 0.2-2mm in 20% of N0 patients

Anatomy

SLN in unexpected locations in 38% of patients+SLN only in unexpected locations in 17% of **pos** patients

Reduced morbidity

overall lymphatic morbidity, early postop events, neurological symptoms, lymphedema, QoL

GYNECOLOGIC CANCER INTERGROUP

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

What next?

- trial for patients with micrometastases
- survival
- qol
- trial for + SLN



An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

GCIG MELBOURNE BRAINSTORMING SYMPSIUM ON CC (2014)

 expand fertility-preserving options with neoadjuvant chemotherapy
 validation of the assessment of sentinel lymph nodes using minimally invasive surgery with an emphasis on identification and management of low-volume metastasis, such as isolated tumor cells and micrometastasis
 evaluation of hypofractionation for palliative and curative radiation under the umbrella of the GCIG Cervix Cancer Research Network
 Adding to the advances in antiangiogenesis therapy in the setting of metastatic disease
 developing a maintenance study among women at high risk of relapse



2015 proposal Schema


SCC/Adk Stage≤IIa <40mm No pregnancy SLN center SLN biopsy Cormier algorithm No dissection if neg

Dissection center SLN biopsy Cormier algorithm syst dissection









GYNECOLOGIC CANCER INTERGROUP

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

Quality assurance

- Centre selection
 - Having participated to SENTICOL, SENTICOL II or other prospective study on SLN in cervical or endometrial cancer
 - OR Treating at least 15 cases of early cervical cancer / year
 - OR Trained for SLN + PLN of at least 15 cases of cervical or endometrial cancer
 - AND Trained for the safety algorythm
 - Use of isotope +/- blue dye (or ICG)
 - Availability of pelvic/abdominal MRI, planar lymphoscintigraphy or SPECT, frozen section
 - Pathologist trained for frozen section of SLN and ultrastaging of SLN
 - Multidisciplinary board, radiation therapy, chemotherapy, clinical research facilities
- Centre assessment
 - Random selection of reports



An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

Present status

- Grant for the French part & international coordination
- Sponsor = CHU de Besançon
- Application to French authorities (May 2017)
- 50 sites in France
- 1st inclusion in February



An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

SENTICOL III: an international task force

- An international study
- Several GCIG groups participation
- Unique opportunity to register data about ECC

GYNECOLOGIC CANCER INTERGROUP

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

SENTIX trial

Observational study

The null hypothesis is that the recurrence rate after SLN biopsy is non-inferior to the reference recurrence rate of 7 % (at the 24th month of follow-up) in patients after systematic pelvic lymphadenectomy, but that the less radical surgery is associated with significantly lower postoperative morbidity.

300 patients

GYNECOLOGIC CANCER INTERGROUP

An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

Thank you !

Contact

fabrice.lecuru@aphp.fr

bvotan@arcagy.org